Comments
Commented by Fabian Lorenz on August 27th, 2025 | 07:00 CEST
TAKEOVER rally and analyst reactions! Puma, CTS Eventim, AJN Resources!
Gold hopes, concert frustration, and takeover speculation—three exciting stories are currently moving the stock market. AJN Resources is starting the next phase of exploration and hopes to find millions of ounces of gold in Ethiopia. To this end, it has a strong partner on board. CTS Eventim shocks investors with weak figures, but analysts remain surprisingly calm. Is the stock now a buy? And at Puma, the possible exit of the Pinault family is causing the biggest jump in the share price in two decades. Is the cult brand facing a takeover from China? Analysts remain skeptical.
Read
Commented by André Will-Laudien on August 26th, 2025 | 07:20 CEST
Big moves! Buying frenzy at Novo Nordisk and PanGenomic Health, Valneva left behind
Things are moving again in the biotech sector! While Novo Nordisk appears to have finally found its footing after three profit warnings, PanGenomic Health continues its upward trend. Since launching its new business model in May, the stock has staged a phenomenal rally of over 1,000%. Meanwhile, Valneva faces a major setback as the US Food and Drug Administration (FDA) has halted approval of the chikungunya vaccine Ixchiq due to severe side effects. This comes as a shock to investors, who are now waiting for the Company to provide further explanations. The stock market has reacted with a sharp drop in the share price. How can investors benefit from the current situation?
Read
Commented by Stefan Feulner on August 26th, 2025 | 07:15 CEST
Freeport-McMoRan, Desert Gold Ventures, Rio Tinto – Investing in the future
What happens after Jackson Hole? Following Federal Reserve Chairman Jerome Powell's speech, which boosted the markets with the prospect of possible interest rate cuts later this year, Nvidia's earnings report on Wednesday will take center stage this week. Any disappointment could cause recent gains to vanish into thin air. Meanwhile, the price of gold remains stable and, after a brief sideways movement, could take off to new heights.
Read
Commented by Armin Schulz on August 26th, 2025 | 07:10 CEST
The blueprint for AI-driven drug discovery: How Evotec, NetraMark Holdings, and BioNTech are leveraging new opportunities
The pharmaceutical industry is undergoing a revolution. Artificial intelligence is reducing drug discovery times from years to months and dramatically increasing hit rates. Data-driven predictions and virtual simulations are increasingly replacing costly trial-and-error approaches. This technological leap is already generating concrete successes and massive competitive advantages for pioneers who implemented their digitalization strategies early on. Most recently, an AI-designed drug advanced to clinical trials in record time. Three companies driving this change and reaping its benefits are Evotec, NetraMark Holdings, and BioNTech.
Read
Commented by Fabian Lorenz on August 26th, 2025 | 07:05 CEST
The defense industry in an Industrial Revolution! Rheinmetall, RENK, and Almonty Industries are benefiting!
The defense industry is at the beginning of a supercycle. This will not change even if peace is achieved in Ukraine, which is hardly more likely after the recent summit. After years of limited capacity, often small-scale production, and difficult financing conditions, the industry is increasingly moving into a new dimension of industrialization. To rapidly rearm Europe, the focus is shifting toward standardized products, larger quantities, and efficiency along the value chain. RENK and Rheinmetall are already following this path. But of course, suppliers must also keep pace. The fact that more tungsten will soon be available outside China is likely to be a blessing for Western defense companies. Almonty has built a state-of-the-art new mine in South Korea. Analysts expect massive increases in revenue and profits.
Read
Commented by Nico Popp on August 26th, 2025 | 07:00 CEST
Two-tier market for raw materials: BHP Group, Power Metallic Mines, BYD
The term "commodity" refers to a standardized, interchangeable product with no unique characteristics. However, this principle is beginning to falter. On the one hand, production conditions are becoming increasingly important for raw materials; on the other, in an era of conflicting power blocs, tariffs, and other trade barriers, raw materials are far from interchangeable. The further processing of raw materials also gives companies in the sector the opportunity to set themselves apart from the competition and generate unique selling points. Commodity? That was yesterday! We explain the current development using the examples of BHP Group, Power Metallic Mines, and BYD, and highlight the opportunities for investors.
Read
Commented by Armin Schulz on August 25th, 2025 | 07:30 CEST
Defense, tungsten, algorithms: Invest in market leaders Rheinmetall, Almonty Industries, and Palantir
In a world undergoing geopolitical upheaval, three key sectors are coming into focus: modern defense technology, critical raw materials, and strategic data analysis. While defense giants are benefiting from rising military budgets, raw material pioneers are satisfying the hunger for materials in the high-tech and defense industries. At the same time, data analysis is monetizing this new complexity for both companies and government security agencies. The successful convergence of these sectors is creating unique growth opportunities. Anyone looking to invest in the defense and security sector should keep an eye on market leaders Rheinmetall, Almonty Industries, and Palantir. They benefit from stability, innovative strength, and reliable growth opportunities.
Read
Commented by Fabian Lorenz on August 25th, 2025 | 07:25 CEST
A bombshell for takeover candidates! 100% share BioNxt Solutions leaves BioNTech and Co. behind!
BioNxt shares have finally taken off. At the beginning of July, we last pointed out the opportunities offered by the Canadian-German life sciences company. Since then, the share price has risen by almost 100%, outperforming both the biotech index and investor favorites like BioNTech. However, this is likely to be just the beginning. In a conversation with the editorial team, management hinted at a strong news flow in the coming months. The Company is working flat out on its next-generation platforms to revolutionize drug delivery. For example, syringes and tablets are to be replaced by dissolvable films and transdermal patches. This not only makes BioNxt a prime acquisition candidate, but with a market capitalization of just CAD 100 million, the Company still appears to be anything but expensive.
Read
Commented by Stefan Feulner on August 25th, 2025 | 07:20 CEST
BYD, Antimony Resources, NIO – Strategically significant steps
The new trading week began with losses, with the DAX, Dow Jones, and, above all, the Nasdaq technology exchange stumbling. However, shortly before the end of the week, the US Federal Reserve, with its controversial chairman Jerome Powell, came out with renewed speculation about interest rate cuts. This triggered a rally that pushed the indices back towards their previous highs. However, caution is still warranted, as many valuations are more than ambitious.
Read
Commented by Nico Popp on August 25th, 2025 | 07:15 CEST
China boosts gold – Now insurers are joining in: Sranan Gold, China Life, Allianz
China is moving the markets. The latest China bombshell concerns gold. Starting this year, Chinese companies are required to invest 1% of their assets in physical gold. This change underscores the Chinese authorities' view that gold is a key anchor of stability for the financial system. Considering the huge capital reserves of Chinese insurers, up to USD 27 billion could flow into the gold market. Analysts are celebrating the additional institutional demand, and companies like China Life are showing strong cooperation. But the best news is yet to come for gold investors.
Read